CN1041166C - 抗菌素与二价和/或三价金属形成的螯合物在制备抗溃疡药中的用途 - Google Patents

抗菌素与二价和/或三价金属形成的螯合物在制备抗溃疡药中的用途 Download PDF

Info

Publication number
CN1041166C
CN1041166C CN91101355A CN91101355A CN1041166C CN 1041166 C CN1041166 C CN 1041166C CN 91101355 A CN91101355 A CN 91101355A CN 91101355 A CN91101355 A CN 91101355A CN 1041166 C CN1041166 C CN 1041166C
Authority
CN
China
Prior art keywords
azithromycin
divalent
antibiotics
gel
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN91101355A
Other languages
English (en)
Chinese (zh)
Other versions
CN1054534A (zh
Inventor
斯罗泊丹·德约基克
斯拉克·瓦特尼尔
沃吉·克吉威斯
尼维卡·罗泊塔
利笛嘉·克拉尼-巴比克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd filed Critical Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Publication of CN1054534A publication Critical patent/CN1054534A/zh
Application granted granted Critical
Publication of CN1041166C publication Critical patent/CN1041166C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN91101355A 1990-03-07 1991-03-06 抗菌素与二价和/或三价金属形成的螯合物在制备抗溃疡药中的用途 Expired - Fee Related CN1041166C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
YU45590A YU45590A (sh) 1990-03-07 1990-03-07 Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
YUP-455/90 1990-03-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN97109555A Division CN1051560C (zh) 1990-03-07 1997-04-18 抗菌素与络合金属盐的螯合物的制备方法

Publications (2)

Publication Number Publication Date
CN1054534A CN1054534A (zh) 1991-09-18
CN1041166C true CN1041166C (zh) 1998-12-16

Family

ID=25550003

Family Applications (2)

Application Number Title Priority Date Filing Date
CN91101355A Expired - Fee Related CN1041166C (zh) 1990-03-07 1991-03-06 抗菌素与二价和/或三价金属形成的螯合物在制备抗溃疡药中的用途
CN97109555A Expired - Fee Related CN1051560C (zh) 1990-03-07 1997-04-18 抗菌素与络合金属盐的螯合物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN97109555A Expired - Fee Related CN1051560C (zh) 1990-03-07 1997-04-18 抗菌素与络合金属盐的螯合物的制备方法

Country Status (20)

Country Link
US (1) US5498699A (enExample)
EP (1) EP0445743B1 (enExample)
JP (1) JP2731636B2 (enExample)
CN (2) CN1041166C (enExample)
AT (1) ATE143266T1 (enExample)
BG (1) BG61230B1 (enExample)
CA (1) CA2037663C (enExample)
CZ (1) CZ280181B6 (enExample)
DE (1) DE69122282T2 (enExample)
DK (1) DK0445743T3 (enExample)
ES (1) ES2094763T3 (enExample)
GR (1) GR3021947T3 (enExample)
HR (1) HRP940256B1 (enExample)
HU (2) HU209455B (enExample)
PL (1) PL166279B1 (enExample)
RO (1) RO107660B1 (enExample)
RU (2) RU2039060C1 (enExample)
SI (1) SI9010455B (enExample)
SK (1) SK279278B6 (enExample)
YU (1) YU45590A (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2064634C (en) * 1991-04-04 1998-08-04 James V. Heck 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
TW271400B (enExample) * 1992-07-30 1996-03-01 Pfizer
FI973117L (fi) * 1995-01-26 1997-09-25 Nycomed Imaging As Vismuttiyhdisteitä
GB9501560D0 (en) * 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
US5900410A (en) * 1996-08-27 1999-05-04 Hartmann; John F. Monotherapy of peptic ulcers and gastritis
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
EA200400214A1 (ru) * 2001-08-21 2004-06-24 Пфайзер Продактс Инк. Азитромицин в виде разовой дозы
RU2283116C2 (ru) * 2002-05-27 2006-09-10 Курский государственный медицинский университет Способ увеличения выживаемости изолированного кожного лоскута "на ножке" у животных с пониженным антиоксидантным фоном
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
US8440646B1 (en) 2006-10-11 2013-05-14 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of Bacillus anthracis infections
CN104892694A (zh) * 2015-05-24 2015-09-09 广西师范学院 蔗糖硫酸酯铜类化合物及其制作方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862225A (en) * 1961-08-18 1975-01-21 Pfizer D-ring substituted tetracyclines
US3622627A (en) * 1967-09-13 1971-11-23 Pfizer 4-dedimethylaminatetracycline and 5a, 6-anhydro derivatives thereof
HU167946B (enExample) * 1973-04-16 1976-01-28
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
EP0222834A4 (en) * 1985-04-18 1989-10-04 Borody Thomas J TREATMENT OF NON-ULCERATIVE DYSPEPSIA WITH BISMUTOUS SALTS.
ATE81010T1 (de) * 1985-06-13 1992-10-15 Barry James Marshall Zusammensetzungen zur behandlung von magendarmst¯rungen.
IT1200774B (it) * 1985-10-10 1989-01-27 Pierrel Spa Procedimento di sentisi dell'amikacina
SI8611592A8 (en) * 1986-09-12 1995-04-30 Pliva Pharm & Chem Works Process for preparing complexes of N-methyl-11-aza-10-deoxo-10-dihydroeritromicine A and 11-aza-10-deoxo-10-dihydroeritromicine A with metals
EP0283055B1 (en) * 1987-09-03 1990-08-29 SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. 10-dihydro-10-deoxo-11-azaerythronolide-a-compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof
EP0439453B1 (en) * 1987-10-12 1994-01-19 Exomed Australia Pty. Ltd. (ACN 051 976 446) Improved method for treatment of gastrointestinal disorders
US5246708A (en) * 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
ES2019267T3 (es) * 1989-04-03 1993-09-16 Ranbaxy Laboratories, Ltd. Un procedimiento para la preparacion de alfa-6-desoxitetraciclinas.
US5348946A (en) * 1991-02-28 1994-09-20 Biochem Immunosystems, Inc. Heteroanthracycline antitumor analogs
MA28714B1 (fr) * 2005-12-15 2007-07-02 Green Technlology Sarl Une arabinogalactane proteine ayant la propriete d'absorber les graisses et le procede d'obtention de cette arabinogalactane proteine

Also Published As

Publication number Publication date
SI9010455A (en) 1997-08-31
CN1054534A (zh) 1991-09-18
HU910740D0 (en) 1991-09-30
JP2731636B2 (ja) 1998-03-25
HRP940256B1 (en) 1998-10-31
SI9010455B (sl) 2000-04-30
DK0445743T3 (enExample) 1997-02-17
RU2039061C1 (ru) 1995-07-09
EP0445743A3 (en) 1992-10-07
BG93995A (bg) 1993-12-24
CA2037663A1 (en) 1991-09-08
DE69122282T2 (de) 1997-04-24
ES2094763T3 (es) 1997-02-01
CN1051560C (zh) 2000-04-19
HU209455B (en) 1994-06-28
CS9100587A2 (en) 1991-10-15
BG61230B1 (bg) 1997-03-31
HUT56849A (en) 1991-10-28
CZ280181B6 (cs) 1995-11-15
CN1168891A (zh) 1997-12-31
RO107660B1 (ro) 1993-12-30
PL166279B1 (pl) 1995-04-28
CA2037663C (en) 1999-01-19
GR3021947T3 (en) 1997-03-31
JPH06184186A (ja) 1994-07-05
EP0445743B1 (en) 1996-09-25
HU211475A9 (en) 1995-11-28
RU2039060C1 (ru) 1995-07-09
HRP940256A2 (en) 1997-06-30
SK279278B6 (sk) 1998-09-09
DE69122282D1 (de) 1996-10-31
ATE143266T1 (de) 1996-10-15
US5498699A (en) 1996-03-12
YU45590A (sh) 1992-07-20
EP0445743A2 (en) 1991-09-11

Similar Documents

Publication Publication Date Title
CN1041166C (zh) 抗菌素与二价和/或三价金属形成的螯合物在制备抗溃疡药中的用途
EP2016045B1 (en) A tigecycline crystalline form and processes for its preparation
AU2004213819B2 (en) Ferric organic compounds, uses thereof and methods of making same
Kong et al. Preparation of Glycy-l-Tyrosine intercalated layered double hydroxide film and its in vitro release behavior
CN1893956A (zh) 多西环素金属络合物固体剂型
CN1159183A (zh) 作为抗癌和抗病毒剂的二-(2-卤代乙基)氨基苯基取代的偏端霉素衍生物
CN1159197A (zh) 链阳菌素的纯化形式、其制备和含有它的药物组合物
CN1950331A (zh) 那格列奈的多晶型物
CN118221560B (zh) 一种纳米抗菌化合物及其制备方法
CN1834088A (zh) 四肽衍生物的晶体
CN1096468C (zh) 阿奇霉素多元酸钠盐复合盐
CN1523029A (zh) 一种阿德福韦酯新的晶型及其制备方法
CN111196839B (zh) 一种硫链丝菌素衍生物及其制备方法
CN1187307C (zh) 一种从(S)－(＋)－2－氟－α－甲基－[1,1'－二苯基]－4－乙酸的拆分母液制备(R)－(－)－2－氟－α－甲基－[1,1'－二苯基]－4－乙酸的方法
CN1842531A (zh) 1－甲基碳青霉烯化合物的结晶
CN1528766A (zh) 草酸阿地福韦酯及其晶型和制备方法及用途
CN1796396A (zh) 胺基糖的晶体
CN101528265A (zh) 西布曲明和β-环糊精的包络物
AT13157U1 (de) Tigecyclin, kristalline Formen und Herstellungsverfahren dafür

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee